Table 2.

Summary of symptoms presents at baseline, that appeared during follow-up and that persisted at finalization of the study, in patients with COVID-19 in treatment group or control group.

Symptom	Total		At baseline		Appeared during follow-up		Persisted at finalization of the study
	HCQ group (n = 87)	Control group (n = 55)	HCQ group (n = 87)	Control group (n = 55)	HCQ group (n = 87)	Control group (n = 55)	HCQ group (n = 87)	Control group (n = 55)
Headache	68 (78.2)	41 (74.5)	60 (69.0)	38 (69.1)	8a (9.2)	3 (5.5)	7 (8.0)	6 (11)
Smell and taste disorders	60 (69.0)	36 (65.5)	47 (54.0)	29 (52.7)	13 (15.0)	7 (12.7)	22 (25.3)	22 (40)
Muscle pain	65 (74.7)	35 (64.0)	62 (71.3)	33 (60.0)	3 (3.4)	2 (3.6)	7 (8.0)	7 (12.7)
Fatigue	63 (72.4)	33 (60.0)	62 (71.3)	32 (58.2)	1 (1.1)	1 (1.8)	12 (13.8)	7 (12.7)
Fever	57 (65.5)	33 (60.0)	52 (59.8)	31 (56.4)	5 (5.7)	2 (3.6)	0	0
Nasal congestion	48 (55.2)	36 (65.5)	44 (50.6)	33 (60.0)	4 (4.6)	3 (5.5)	8 (9.2)	4 (7.3)
Cough	65 (74.7)	34 (62.0)	60 (69.0)	29 (52.7)	5 (5.7)	5 (9.1)	10 (11.5)	8 (14.5)
Sore throat	49 (56.3)	22 (40.0)	45 (51.7)	21 (38.2)	4 (4.6)	1 (1.8)	2 (2.3)	2 (3.6)
Anorexia	35 (40.2)	15 (27.3)	31 (35.6)	15 (27.3)	4 (4.6)	0	6 (6.9)	1 (1.8)
Shortness of breath	23 (26.4)	17 (31.0)	19 (21.8)	13 (23.6)	4 (4.6)	4 (7.3)	3 (3.4)	4 (7.3)
Diarrhea	42 (48.3)	17 (31.0)	17 (19.5)	12 (21.8)	25a (27.6)	5 (9.1)	2 (2.3)	3 (5.5)
Chest pain	9 (10.3)	10 (18.2)	9 (10.3)	7 (12.7)	0	3 (5.5)	1 (1.1)	4 (7.3)
Sputum production	17 (19.5)	5 (9.1)	15 (17.2)	5 (9.1)	2 (2.3)	0	3 (3.4)	3 (5.5)
Eye discomfort	12 (13.8)	4 (7.27)	10 (11.5)	4 (7.3)	2 (2.3)	0	3 (3.4)	2 (3.6)

Data are n (%)

^aIn 4 cases of headache and 25 of diarrhea side effects of HCQ treatment could not be excluded as the cause of the symptom.